Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial-Reference-Cited by-同舟云学术

Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial

Published:2023-05 Issue: Volume:182 Page:109576
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Eufemon Cereno Reno,Mou Benjamin,Baker Sarah,Chng Nick,Arbour Gregory,Bergman Alanah,Liu Mitchell,Schellenberg Devin,Matthews Quinn,Huang Vicky,Mestrovic Ante,Hyde Derek,Alexander Abraham,Carolan Hannah,Hsu Fred,Miller Stacy,Atrchian Siavash,Chan Elisa,Ho Clement,Mohamed Islam,Lin Angela,Berrang Tanya,Bang Andrew,Jiang Will,Lund Chad,Pai Howard,Valev Boris,Lefresne Shilo,Tyldesley Scott,Olson Robert A.

Funder

AstraZeneca

Varian Medical Systems

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology

Reference27 articles.

1. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial;Palma;Lancet,2019

2. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET Phase II randomized trial;Palma;J Clin Oncol,2020

3. Harrow S, Palma DA, Olson R, et al. Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes. Int J Radiat Oncol Biol Phys. Published online 2022. doi:10.1016/j.ijrobp.2022.05.004

4. SABR-COMET: harbinger of a new cancer treatment paradigm;Loo;Lancet,2019

5. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study;Gomez;Lancet Oncol,2016

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acute toxicity in patients with oligometastatic cancer following metastasis-directed stereotactic body radiotherapy: An interim analysis of the E2-RADIatE OligoCare cohort;Radiotherapy and Oncology;2024-10

2. Prospective phase II trial on ablative stereotactic body radiation therapy (SBRT) for medically inoperable thoracic nodes metastases;Radiotherapy and Oncology;2024-08

3. Factors influencing local control after MR-guided stereotactic body radiotherapy (MRgSBRT) for adrenal metastases;Clinical and Translational Radiation Oncology;2024-05

4. Predictors of Quality of Life Decline in Patients with Oligometastases treated with Stereotactic Ablative Radiotherapy: Analysis of the Population-Based SABR-5 Phase II Trial;Clinical Oncology;2024-03

5. MR-guided stereotactic radiotherapy of infra-diaphragmatic oligometastases: Evaluation of toxicity and dosimetric parameters;Radiotherapy and Oncology;2024-03